Please wait





Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
Checkbox checked   Rule 13d-1(b)
Checkbox not checked   Rule 13d-1(c)
Checkbox not checked   Rule 13d-1(d)






SCHEDULE 13G




Comment for Type of Reporting Person:   (1) The figures in Items 6, 8, and 9 represent common stock, $0.0001 par value per share ("Common Stock") of Tenax Therapeutics, Inc. (the "Issuer") held by Ikarian Healthcare Master Fund, L.P., a Cayman Islands exempted limited partnership (the "Fund"), and certain separate managed accounts. See Item 2 for more information. (2) The figure in Item 11 is based upon 4,562,500 shares of Common Stock outstanding as of August 11, 2025, as disclosed in the Issuer's quarterly report on Form 10-Q for the quarterly period ended June 30, 2025, filed with the U.S. Securities and Exchange Commission (the "SEC") on August 13, 2025.


SCHEDULE 13G




Comment for Type of Reporting Person:   (1) The figures in Items 6, 8, and 9 represent Common Stock of the Issuer held by the Fund and certain separate managed accounts. See Item 2 for more information. (2) The figure in Item 11 is based upon 4,562,500 shares of Common Stock outstanding as of August 11, 2025, as disclosed in the Issuer's quarterly report on Form 10-Q for the quarterly period ended June 30, 2025, filed with the SEC on August 13, 2025.


SCHEDULE 13G



 
Ikarian Capital, LLC
 
Signature:/s/ Neil Shahrestani
Name/Title:Neil Shahrestani, Sole Manager
Date:10/07/2025
 
Neil Shahrestani
 
Signature:/s/ Neil Shahrestani
Name/Title:Neil Shahrestani
Date:10/07/2025